Skip to content

A clinical study of different doses of budesonide/formoterol for the treatment of cough variant asthma

A clinical study of different doses of budesonide/formoterol for the treatment of cough variant asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOD-16008838
Enrollment
Unknown
Registered
2016-07-14
Start date
2016-08-01
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cough variant asthma

Interventions

Two groups:budesonide/formoterol

Sponsors

Second Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. All subjects agreed to participate, understand the project, observe the use of drugs, agree to follow-up, and signed informed consent; 2. aged 18 to 70 years old male and female; 3. The duration time was more than 8 weeks,and cough was usually the only complaint, without breathing, short of breath, chronic cough.Often accompanied by irritant cough at night and (or) in the early morning. Aggravated after exercise. 4. A diagnosis of asthma supported by one or more other characteristics: (1) bronchial provocation test positive; (2) improvement in FEV1 of more than 12% and 200 mL after inhaled salbutamol; (3) variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week. 5. Bronchodilator and glucocorticoid treatment is effective.

Exclusion criteria

Exclusion criteria: 1. Can not cooperate with related inspection or for other reasons; 2. Patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and companied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, GERD, neuromuscular disease, etc); 3. History of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study; 4. taking part in other drug clinical trial project, or drop out less than 3 months; 5. during pregnancy, lactation women

Design outcomes

Primary

MeasureTime frame
daily cough symptom score;

Secondary

MeasureTime frame
LCQ life quality score;the improvement of pulmonary function;ER/ hospital visits for uncontrolled cough;Acute episoded cough;

Countries

China

Contacts

Public ContactWen Li

Second Affiliated Hospital, Zhejiang University School of Medicine

liwenzjhz0408@163.com+86 0571-88981915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026